Adverse reactions of local anesthetics

2021 ◽  
Vol 90 (4) ◽  
pp. 65-68
Author(s):  
V.V. Unzhakov ◽  
Keyword(s):  
Side Effects ◽  
Local Anesthetics ◽  
Adverse Reactions ◽  
Systemic Toxicity ◽  
Regulatory Documents ◽  
Higher Doses

The article explains the adverse reactions of local anesthetics, in particular one of them, called the toxicity of local anesthetics. It has been shown that for the development of systemic toxicity of local anesthetics, higher doses of the latter are required in comparison with those recommended in the instructions. It is proposed in the regulatory documents to replace the term 'toxicity of local anesthetics' with the term 'side effects of local anesthetics'

scholarly journals Disputed issues of systemic toxicity of local anesthetics

2020 ◽  
Vol 16 (1) ◽  
pp. 46-51
Author(s):  
V. V. Unzhakov ◽  
E. S. Netesin ◽  
V. I. Gorbachev
Keyword(s):  
Clinical Practice ◽  
Side Effects ◽  
Local Anesthetics ◽  
Systemic Toxicity ◽  
Legal Issues ◽  
World Health ◽  
Regulatory Documents ◽  
Lipid Resuscitation ◽  
Health Organization

Objective: assessment of the "systemic toxicity of local anesthetics,” term validity, and a legal appraisal of the term “lipid resuscitation.” Regulatory documents and specialized literature devoted to the terminology of toxicity of local anesthetics were reviewed and analyzed. The article presents the classification of the adverse events proposed by World Health Organization experts. The legal issues related to the so-called “lipid resuscitation” are discussed. It seems appropriate to replace the term “systemic toxicity” of local anesthetics in all official documents with the term “side effect of the drug” or “side effects.” The use of the “lipid resuscitation” term in clinical practice is not supported by regulatory documents.

scholarly journals Dentists' knowledge regarding signs and symptoms of the systemic toxicity of local anesthetic solutions

2015 ◽  
Vol 63 (1) ◽  
pp. 41-46
Author(s):  
Ana Carolina PINHEIRO ◽  
Jayne França MARQUES ◽  
Mayana Soares VIEIRA ◽  
Luciana Salles BRANCO-DE-ALMEIDA
Keyword(s):  
Side Effects ◽  
Local Anesthetic ◽  
Local Anesthetics ◽  
Selection Criteria ◽  
Signs And Symptoms ◽  
Individual Characteristics ◽  
Systemic Toxicity ◽  
Dental Clinics ◽  
General Dentists ◽  
Toxic Concentrations

OBJECTIVE: To evaluate the knowledge of dentists about signs and symptoms that may be indicative of systemic toxicity associated with the use of local anesthetic solutions. METHODS: One hundred and twenty-four (124) dentists from private clinics in São Luís (Maranhão, Brazil) answered a questionnaire regarding the choice of solutions, selection criteria for local anesthetics and vasoconstrictors, and side effects associated with these substances. Results were analyzed by using descriptive statistics. RESULTS: Although most respondents reported being likely to choose local anesthetics at less toxic concentrations (including 2% mepivacaine or lidocaine), they were also likely to have similar vasoconstrictor solutions (epinephrine) as the second choice. The main selection criteria of anesthetic solutions reported were the duration of procedures and patients' individual characteristics. In general, dentists demonstrated being aware of some side effects associated with vasoconstrictors; however, they showed a lack of knowledge regarding signs and symptoms related to an overdose of local anesthetics. CONCLUSION: The group of dentists involved in this study showed limited knowledge about the toxicity of local anesthetics, as well as some inconsistent background over the choice of vasoconstrictors. Thus, strategies are required towards improving the knowledge of professionals from private dental clinics regarding local anesthetics and/or vasoconstrictors.

scholarly journals Lidocaine: A Local Anesthetic, Its Adverse Effects and Management

Medicina ◽  
2021 ◽  
Vol 57 (8) ◽  
pp. 782
Author(s):  
Entaz Bahar ◽  
Hyonok Yoon
Keyword(s):  
Adverse Effects ◽  
Local Anesthetic ◽  
Local Anesthetics ◽  
Adverse Reactions ◽  
Rapid Diagnosis ◽  
Diagnosis And Treatment ◽  
Allergic Reactions ◽  
Life Threatening

The most widely used medications in dentistry are local anesthetics (LA), especially lidocaine, and the number of recorded adverse allergic responses, particularly of hazardous responses, is quite low. However, allergic reactions can range from moderate to life-threatening, requiring rapid diagnosis and treatment. This article serves as a review to provide information on LA, their adverse reactions, causes, and management.

scholarly journals The Safety of COVID-19 Vaccinations—We Should Rethink the Policy

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 693
Author(s):  
Harald Walach ◽  
Rainer J. Klement ◽  
Wouter Aukema
Keyword(s):  
Side Effects ◽  
Confidence Interval ◽  
Field Study ◽  
Adverse Reactions ◽  
Safety Data ◽  
European Medicines Agency ◽  
Point Estimate ◽  
Drug Reactions ◽  
Vaccination Policy ◽  
Risks And Benefits

Background: COVID-19 vaccines have had expedited reviews without sufficient safety data. We wanted to compare risks and benefits. Method: We calculated the number needed to vaccinate (NNTV) from a large Israeli field study to prevent one death. We accessed the Adverse Drug Reactions (ADR) database of the European Medicines Agency and of the Dutch National Register (lareb.nl) to extract the number of cases reporting severe side effects and the number of cases with fatal side effects. Result: The NNTV is between 200–700 to prevent one case of COVID-19 for the mRNA vaccine marketed by Pfizer, while the NNTV to prevent one death is between 9000 and 50,000 (95% confidence interval), with 16,000 as a point estimate. The number of cases experiencing adverse reactions has been reported to be 700 per 100,000 vaccinations. Currently, we see 16 serious side effects per 100,000 vaccinations, and the number of fatal side effects is at 4.11/100,000 vaccinations. For three deaths prevented by vaccination we have to accept two inflicted by vaccination. Conclusions: This lack of clear benefit should cause governments to rethink their vaccination policy.

scholarly journals DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1046
Author(s):  
Gerardo Casucci ◽  
Domenico Acanfora
Keyword(s):  
Side Effects ◽  
Disseminated Intravascular Coagulation ◽  
Adverse Reactions ◽  
Thrombus Formation ◽  
European Countries ◽  
European Medicines Agency ◽  
Safety Committee ◽  
Vectored Vaccine ◽  
Short Time ◽  
Prompt Diagnosis

In recent weeks, adverse reactions have been reported after administration of Oxford–AstraZeneca chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19 (AZD1222), in particular thrombus formation, which has led several European Countries to discontinue administration of this vaccine. On March 8, 2021, the European Medicines Agency Safety Committee did not confirm this probable association. We report the case of a patient who developed disseminated intravascular coagulation after the first dose of Oxford-Astra Zeneca vaccine, which resolved in a few days with the administration of dexamethasone and enoxaparin. This work demonstrates the safety of the Oxford-Astra Zeneca vaccine and that any development of side effects can be easily managed with a prompt diagnosis and in a short time with a few commonly used drugs.

scholarly journals Evaluation of medicines advertising in medical journals

2009 ◽  
Vol 45 (2) ◽  
pp. 303-312
Author(s):  
Daliana Maria Berenice de Oliveira Souza ◽  
Suellen Cristiane Medeiros de Lima ◽  
Almária Mariz Batista ◽  
Maria Cleide Ribeiro Dantas de Carvalho
Keyword(s):  
Side Effects ◽  
Adverse Reactions ◽  
Healthcare Professionals ◽  
Scientific Information ◽  
Medical Prescription ◽  
Medical Journals ◽  
Registration Number ◽  
The Common

This work intended to analyze the advertising of medicines requiring medical prescription, divulged into three journals of the neurology and cardiology areas addressed to healthcare professionals. The analysis was based on current legislation, among other criteria, as well as specific literature. The presence of the following items was investigated: registration number, drug name, specific indications, contraindications; cautions and warnings; adverse reactions; possible side effects; posology; legibility of technical-scientific information and bibliographic references, phrases and/or expressions about the medication benefits, as compared to other drugs; safety warnings, healing promises and pictures of people smiling, and the quotations confirmation based on bibliographic references. Among the evaluated legal criteria, it was observed the absence of legibility in technical-scientific information in 85% of advertisements; absence of side effects in 23%; absence of cautions and warnings in 15%; of contraindications in 12.8%; of posology in 6.4%; of registration numbers in 2.7% and of the Common Brazilian Denomination/Common International Denomination (Denominação Comum Brasileira/Denominação Comum Internacional - DCB/DCI) in 0.6%. Out of 130 statements respecting advantages face to others drugs, 23.8% were not confirmed and out of 48 divulged safety messages, 41.7% could not be found in quoted references. The pictures of people smiling was a resource used in 42.2% of advertisements. Out of 1362 references analyzed, 19.7% were not found and 37.1% of quoted affirmations weren't confirmed.

Adverse Reactions to Local Anesthetics

2019 ◽  
pp. 177-201
Author(s):  
Gari Purcell-Jones ◽  
Felicity Reynolds
Keyword(s):  
Local Anesthetics ◽  
Adverse Reactions

scholarly journals Rheumatological Adverse Events Following Immunotherapy for Cancer

Medicina ◽  
2022 ◽  
Vol 58 (1) ◽  
pp. 94
Author(s):  
Ioana Cretu ◽  
Bogdan Cretu ◽  
Catalin Cirstoiu ◽  
Adrian Cursaru ◽  
Mihaela Milicescu ◽  
...  
Keyword(s):  
Side Effects ◽  
Adverse Events ◽  
Adverse Reactions ◽  
Cancer Treatments ◽  
Treatment Conditions ◽  
Clinical Presentations ◽  
Rheumatic Manifestations ◽  
Grade 3 ◽  
Dose Dependent ◽  
Rheumatological Manifestations

Background and Objectives: The occurrence of rheumatological side effects in a patient after receiving immunotherapy for cancer is becoming increasingly common. Oncologists often fail to diagnose and refer affected patients to rheumatologists. This paper presents the various rheumatological adverse events that occur after immunotherapy in patients as well as their treatment and evolution. Materials and Methods: A total of 36 patients were monitored between November 2018 and March 2020. The oncologist monitoring the immunotherapy-treated patients identified the occurrence of musculoskeletal side effects. The grading of toxicities was performed by both the oncologist and the rheumatologist using common terminology criteria for adverse events (CTCAE). Rheumatological treatment was administered, and for some patients, immunotherapy was discontinued. Results: The clinical presentations of the patients varied. Mild side effects (grade 1–2) were reported in a higher proportion than severe side effects (grade 3–5). Therefore, thirty-one patients had mild-to-moderate side effects, and five patients had severe side effects. Adverse reactions occurred, on average, 10 weeks after the initiation of immunotherapy; this indicated that the severity of the toxicity was dose dependent. Patients were treated with NSAIDs or prednisone, depending on the severity of the side effects, and for patients with severe manifestations, immunotherapy was discontinued. The remission of rheumatic manifestations varied depending on the grade of the manifestations. Conclusions: The clinical, biological, and ultrasound presentations of the patients with adverse events followed by cancer treatments differed from classic rheumatological manifestations. Thorough examinations of these patients by both oncologists and rheumatologists are needed in order to correctly diagnose and treat rheumatological adverse events. Multiple studies that include a larger number of participants are needed in order to better understand the pathogenesis and clinical evolution of these patients under different treatment conditions.

Sign in / Sign up

Export Citation Format

Share Document